Expression of hBD-2 induced by 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b vaccine and split influenza virus vaccine

Shen,Zhenwei; Lei,Han

doi:10.3892/mmr.2012.1005

Expression of hBD-2 induced by 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b vaccine and split influenza virus vaccine

Authors:
- Zhenwei Shen
- Han Lei
View Affiliations

Affiliations: Department of Intensive Care Unit, Eastern Hospital, Tongji University, Shanghai 200120, P.R. China, Department of Respiratory Medicine, Eastern Hospital, Tongji University, Shanghai 200120, P.R. China
Published online on: July 26, 2012 https://doi.org/10.3892/mmr.2012.1005
Pages: 733-738

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human β-defensin-2 (hBD-2) is an antimicrobial peptide with high activity and broad spectrum activity. hBD-2 expression may be highly elevated by microorganisms and inflammation. We reported that the majority of common vaccines used, including 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b vaccine and split influenza virus vaccine, could induce the expression of hBD-2 in epithelial cells. Among them, the 23-valent pneumococcal polysaccharide vaccine was effective at a lower concentration (0.5 µg/ml), while Haemophilus influenzae type b vaccine and split influenza virus vaccine were effective at the concentration of 1 µg/ml. However, bacteriostatic experiments revealed that the split influenza virus vaccine was capable of inducing the highest antimicrobial activity. The medium of the 23-valent pneumococcal polysaccharide vaccine treatment group had a higher antimicrobial activity than the medium of the Haemophilus influenzae type b vaccine treatment group. The transcriptional regulator of hBD-2, that is, the NF-κB subunit, had a high level of activity, while the normal epithelial cells showed barely detectable activity, indicating that these vaccines have potential for clinical application.

View Figures

View References

1	Lehrer RI: Primate defensins. Nat Rev Microbiol. 2:727–738. 2004. View Article : Google Scholar : PubMed/NCBI
2	Pazgier M, Hoover DM, Yang D, Lu W and Lubkowski J: Human beta-defensins. Cell Mol Life Sci. 63:1294–1313. 2006. View Article : Google Scholar
3	Rodriguez-Jimenez FJ, Krause A, Schulz S, et al: Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics. 81:175–183. 2003. View Article : Google Scholar : PubMed/NCBI
4	Schroder JM and Harder J: Human beta-defensin-2. Int J Biochem Cell Biol. 31:645–651. 1999. View Article : Google Scholar
5	Liu L, Wang L, Jia HP, et al: Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation. Gene. 222:237–244. 1998. View Article : Google Scholar : PubMed/NCBI
6	Hiratsuka T, Nakazato M, Date Y, et al: Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. Biochem Biophys Res Commun. 249:943–947. 1998. View Article : Google Scholar : PubMed/NCBI
7	Bals R, Wang X, Wu Z, et al: Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest. 102:874–880. 1998. View Article : Google Scholar : PubMed/NCBI
8	Singh PK, Jia HP, Wiles K, et al: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA. 95:14961–14966. 1998. View Article : Google Scholar : PubMed/NCBI
9	Chen CI, Schaller-Bals S, Paul KP, Wahn U and Bals R: Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros. 3:45–50. 2004. View Article : Google Scholar : PubMed/NCBI
10	Harder J, Bartels J, Christophers E and Schröder JM: A peptide antibiotic from human skin. Nature. 387:8611997. View Article : Google Scholar : PubMed/NCBI
11	Hall RM and Collis CM: Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist Updat. 1:109–119. 1998. View Article : Google Scholar : PubMed/NCBI
12	Partridge SR: Analysis of antibiotic resistance regions in Gram-negative bacteria. FEMS Microbiol Rev. 35:820–855. 2011. View Article : Google Scholar : PubMed/NCBI
13	Boucher HW, Talbot GH, Bradley JS, et al: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 48:1–12. 2009.
14	Slama TG: Gram-negative antibiotic resistance: there is a price to pay. Crit Care. 12(Suppl 4): S42008. View Article : Google Scholar : PubMed/NCBI
15	Peleg AY and Hooper DC: Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 362:1804–1813. 2010. View Article : Google Scholar : PubMed/NCBI
16	Mauldin PD, Salgado CD, Hansen IS, Durup DT and Bosso JA: Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother. 54:109–115. 2010. View Article : Google Scholar : PubMed/NCBI
17	Siegel RE: Emerging gram-negative antibiotic resistance: daunting challenges, declining sensitivities, and dire consequences. Respir Care. 53:471–479. 2008.PubMed/NCBI
18	Chopra I, Schofield C, Everett M, et al: Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis. 8:133–139. 2008. View Article : Google Scholar : PubMed/NCBI
19	Xu B, Dong CY, Zhang F, Lin YM, Wu KF and Ma XT: Synergistic antileukemia effect of combinational gene therapy using murine beta-defensin 2 and IL-18 in L1210 murine leukemia model. Gene Ther. 14:1181–1187. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yin C, Dang HN, Gazor F and Huang GT: Mouse salivary glands and human beta-defensin-2 as a study model for antimicrobial gene therapy: technical considerations. Int J Antimicrob Agents. 28:352–360. 2006. View Article : Google Scholar : PubMed/NCBI
21	Harvey SA, Romanowski EG, Yates KA and Gordon YJ: Adenovirus-directed ocular innate immunity: the role of conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic human defensin-alpha. Invest Ophthalmol Vis Sci. 46:3657–3665. 2005. View Article : Google Scholar : PubMed/NCBI
22	Meyerholz DK, Grubor B, Gallup JM, et al: Adenovirus-mediated gene therapy enhances parainfluenza virus 3 infection in neonatal lambs. J Clin Microbiol. 42:4780–4787. 2004. View Article : Google Scholar : PubMed/NCBI
23	Bals R, Weiner DJ, Moscioni AD, Meegalla RL and Wilson JM: Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun. 67:6084–6089. 1999.PubMed/NCBI
24	Gaudreault E and Gosselin J: Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J Immunol. 180:6211–6221. 2008. View Article : Google Scholar : PubMed/NCBI
25	Alekseeva L, Huet D, Femenia F, et al: Inducible expression of beta defensins by human respiratory epithelial cells exposed to Aspergillus fumigatus organisms. BMC Microbiol. 9:332009. View Article : Google Scholar : PubMed/NCBI
26	Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW and Dale DA: Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun. 68:2907–2915. 2000.PubMed/NCBI
27	Liu AY, Destoumieux D, Wong AV, et al: Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol. 118:275–281. 2002. View Article : Google Scholar : PubMed/NCBI
28	Kanda N, Tada Y, Shimizu T and Watanabe S: IL-12, IL-23, and IL-27 enhance human beta-defensin-2 production in human keratinocytes. J Invest Dermatol. 38:1287–1296. 2008.PubMed/NCBI
29	Tsutsumi-Ishii Y and Nagaoka I: NF-kappa B-mediated transcriptional regulation of human beta-defensin-2 gene following lipopolysaccharide stimulation. J Leukoc Biol. 71:154–162. 2002.PubMed/NCBI
30	Yoon YM, Lee JY, Yoo D, et al: Bacteroides fragilis enterotoxin induces human beta-defensin-2 expression in intestinal epithelial cells via a mitogen-activated protein kinase/I kappa B kinase/NF-kappa B-dependent pathway. Infect Immun. 78:2024–2033. 2010. View Article : Google Scholar
31	Wehkamp J, Harder J, Wehkamp K, et al: NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. 72:5750–5758. 2004.PubMed/NCBI
32	Palkowitsch L, Marienfeld U, Brunner C, Eitelhuber A, Krappmann D and Marienfeld RB: The Ca²⁺-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation. J Biol Chem. 286:7522–7534. 2011.PubMed/NCBI
33	Lavigne JP, Brunel JM, Chevalier J and Pages JM: Squalamine, an original chemosensitizer to combat antibiotic-resistant gram-negative bacteria. J Antimicrob Chemother. 65:799–801. 2010. View Article : Google Scholar : PubMed/NCBI